Webinar: Chronic Kidney Disease: Detection and its Association with Cardiovascular Disease in Clinical Care and Clinical Trials

Chronic Kidney Disease (CKD) is a global epidemic yet is widely under-recognized. Diabetes, the leading cause of CKD, and the burden of associated cardiovascular disease (CVD), contributes to CKD morbidity and mortality. Many patients do not receive the proper attention in management of their risk factors, partially due to physicians' under-detection for CKD as well as the somewhat asymptomatic nature of CKD. Often, this delay in timely detection of CKD results in patients requiring dialysis or renal replacement therapy in the form of kidney transplantation. Managing CKD patients also has several negative implications, which can impact drug development advances for renal therapies. Since 2007, only eight new molecular entities have been approved by the FDA for CKD patients, a statistic that highlights the opportunity to improve screening and management of CKD patients, as well as a need to ensure patients are involved in more clinical trials that can ultimately facilitate approvals for more novel therapies.